Login to Your Account



Targeting tau: Taurx completes enrollment in phase III Alzheimer's trial

By Michael Fitzhugh
Staff Writer

Monday, September 22, 2014
Taurx Therapeutics Ltd. hit full enrollment in the second of two phase III trials of LMTX, the company's tau aggregation inhibitor (TAI) for the treatment of Alzheimer's disease. The multicenter, placebo-controlled trial will assess the therapy's efficacy in 700 subjects with mild Alzheimer's disease over as much as 21 months through both clinical assessments and brain imaging.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription